Ra Pharmaceuticals (NASDAQ:RARX) Downgraded by BidaskClub

BidaskClub lowered shares of Ra Pharmaceuticals (NASDAQ:RARX) from a hold rating to a sell rating in a report released on Tuesday morning, BidAskClub reports.

Several other analysts have also commented on the stock. Zacks Investment Research raised shares of Ra Pharmaceuticals from a hold rating to a buy rating and set a $24.00 price objective on the stock in a research report on Tuesday. Svb Leerink assumed coverage on shares of Ra Pharmaceuticals in a research report on Wednesday, May 22nd. They issued an outperform rating and a $33.00 price objective on the stock. Leerink Swann assumed coverage on shares of Ra Pharmaceuticals in a research report on Wednesday, May 22nd. They issued an outperform rating and a $23.30 price objective on the stock. SunTrust Banks lifted their price objective on shares of Ra Pharmaceuticals to $42.00 and gave the stock a buy rating in a research report on Friday, May 17th. Finally, Raymond James set a $49.00 price objective on shares of Ra Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, April 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the stock. Ra Pharmaceuticals presently has an average rating of Buy and an average price target of $37.23.

Shares of RARX stock opened at $20.99 on Tuesday. The stock has a market capitalization of $840.99 million, a price-to-earnings ratio of -10.19 and a beta of 0.80. The company has a debt-to-equity ratio of 0.02, a quick ratio of 20.10 and a current ratio of 20.10. Ra Pharmaceuticals has a 52 week low of $8.13 and a 52 week high of $27.68.

Ra Pharmaceuticals (NASDAQ:RARX) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.02. Research analysts predict that Ra Pharmaceuticals will post -1.98 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of RARX. Bank of New York Mellon Corp increased its stake in shares of Ra Pharmaceuticals by 12.1% in the third quarter. Bank of New York Mellon Corp now owns 53,759 shares of the company’s stock worth $973,000 after purchasing an additional 5,797 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Ra Pharmaceuticals by 19.4% in the third quarter. JPMorgan Chase & Co. now owns 313,700 shares of the company’s stock worth $5,674,000 after purchasing an additional 51,010 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Ra Pharmaceuticals by 9.1% in the third quarter. Vanguard Group Inc. now owns 739,337 shares of the company’s stock worth $13,374,000 after purchasing an additional 61,929 shares in the last quarter. Quantamental Technologies LLC purchased a new position in shares of Ra Pharmaceuticals in the fourth quarter worth about $44,000. Finally, Rhumbline Advisers increased its stake in shares of Ra Pharmaceuticals by 45.0% in the fourth quarter. Rhumbline Advisers now owns 20,725 shares of the company’s stock worth $377,000 after purchasing an additional 6,432 shares in the last quarter. Hedge funds and other institutional investors own 94.97% of the company’s stock.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Featured Story: Earnings Reports

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.